[1]
|
Nakeeb, A., Pitt, H.A., Sohn, T.A., Coleman, J., Abrams, R.A., Piantadosi, S., Hruban, R.H., Lillemoe, K.D., Yeo, C.J. and Cameron, J.L. (1996) Cholangiocarcinoma. A Spectrum of Intrahepatic, Perihilar, and Distal Tumors. Annals of Sur-gery, 224, 463-475. https://doi.org/10.1097/00000658-199610000-00005
|
[2]
|
Razumilava, N. and Gores, G.J. (2014) Cholangiocarcinoma. The Lancet, 383, 2168-2179.
https://doi.org/10.1016/S0140-6736(13)61903-0
|
[3]
|
Okuda, K., Nakanuma, Y. and Miyazaki, M. (2002) Cholan-giocarcinoma: Recent Progress. Part 1: Epidemiology and Etiology. Journal of Gastroenterology and Hepatology, 17, 1049-1055.
https://doi.org/10.1046/j.1440-1746.2002.02781.x
|
[4]
|
Nathan, H., Aloia, T.A., Vauthey, J.N., Abdalla, E.K., Zhu, A.X., Schulick, R.D., Choti, M.A. and Pawlik, T.M. (2009) A Proposed Staging System for Intrahepatic Cholangiocar-cinoma. Annals of Surgical Oncology, 16, 14-22.
https://doi.org/10.1245/s10434-008-0180-z
|
[5]
|
Brown, K.M., Parmar, A.D. and Geller, D.A. (2014) Intrahepatic Cholangiocarcinoma. Surgical Oncology Clinics of North America, 23, 231-246. https://doi.org/10.1016/j.soc.2013.10.004
|
[6]
|
Khan, A.S. and Dageforde, L.A. (2019) Cholangiocarcinoma. Sur-gical Clinics of North America, 99, 315-335.
https://doi.org/10.1016/j.suc.2018.12.004
|
[7]
|
Welzel, T.M., Mellemkjaer, L., Gloria, G., et al. (2007) Risk Factors for Intrahepatic Cholangiocarcinoma in a Low-Risk Population: A Nationwide Case-Control Study. International Journal of Cancer, 120, 638-641.
https://doi.org/10.1002/ijc.22283
|
[8]
|
Donato, F., Gelatti, U., Tagger, A., et al. (2001) Intrahepatic Cholangiocar-cinoma and Hepatitis C and B Virus Infection, Alcohol Intake, and Hepatolithiasis: A Case-Control Study in Italy. Can-cer Causes & Control, 12, 959-964.
https://doi.org/10.1023/A:1013747228572
|
[9]
|
El-Serag, H.B., Engels, E.A., Landgren, O., et al. (2009) Risk of Hepatobiliary and Pancreatic Cancers after Hepatitis C Virus Infection: A Population-Based Study of U.S. Veterans. Hepatology, 49, 116-123.
https://doi.org/10.1002/hep.22606
|
[10]
|
Shaib, Y.H., El-Serag, H.B., Davila, J.A., Morgan, R. and McGlynn, K.A. (2005) Risk Factors of Intrahepatic Cholangiocarcinoma in the United States: A Case-Control Study. Gastroenterology, 128, 620-626.
https://doi.org/10.1053/j.gastro.2004.12.048
|
[11]
|
Lee, T.Y., Lee, S.S., Jung, S.W., et al. (2008) Hepatitis B Virus Infection and Intrahepatic Cholangiocarcinoma in Korea: A Case-Control Study. American Journal of Gastroenterology, 103, 1716-1720.
https://doi.org/10.1111/j.1572-0241.2008.01796.x
|
[12]
|
Zhou, Y.M., Yin, Z.F., Yang, J.M., et al. (2008) Risk Factors for Intrahepatic Cholangiocarcinoma: A Case-Control Study in China. World Journal of Gastroenterology, 14, 632-635. https://doi.org/10.3748/wjg.14.632
|
[13]
|
Sekiya, S. and Suzuki, A. (2012) Intrahepatic Cholangiocarci-noma Can Arise from Notch-Mediated Conversion of Hepatocytes. Journal of Clinical Investigation, 122, 3914-3918. https://doi.org/10.1172/JCI63065
|
[14]
|
Yamamoto, S., Kubo, S., Hai, S., et al. (2004) Hepatitis C Virus Infection as a Likely Etiology of Intrahepatic Cholangiocarcinoma. Cancer Science, 95, 592-595. https://doi.org/10.1111/j.1349-7006.2004.tb02492.x
|
[15]
|
Chapman, M.H., Webster, G.J., Bannoo, S., Johnson, G.J., Wittmann, J. and Pereira, S.P. (2012) Cholangiocarcinoma and Dominant Strictures in Patients with Primary Scle-rosing Cholangitis: A 25-year Single-Centre Experience. European Journal of Gastroenterology & Hepatology, 24, 1051-1058. https://doi.org/10.1097/MEG.0b013e3283554bbf
|
[16]
|
Bergquist, A., Ekbom, A., Olsson, R., et al. (2002) Hepatic and Extrahepatic Malignancies in Primary Sclerosing Cholangitis. Journal of Hepatology, 36, 321-327. https://doi.org/10.1016/S0168-8278(01)00288-4
|
[17]
|
Chapman, R., Fevery, J., Kalloo, A., et al. (2010) Diagnosis and Management of Primary Sclerosing Cholangitis. Hepatology, 51, 660-678. https://doi.org/10.1002/hep.23294
|
[18]
|
Claessen, M.M., Vleggaar, F.P., Tytgat, K.M., Siersema, P.D. and van Buuren, H.R. (2009) High Lifetime Risk of Cancer in Primary Sclerosing Cholangitis. Journal of Hepatology, 50, 158-164.
https://doi.org/10.1016/j.jhep.2008.08.013
|
[19]
|
Kaewpitoon, N., Kaewpitoon, S.J., Pengsaa, P. and Sripa, B. (2008) Opisthorchis Viverrini: The Carcinogenic Human Liver Fluke. World Journal of Gastroenterology, 14, 666-674. https://doi.org/10.3748/wjg.14.666
|
[20]
|
Shin, H.R., Lee, C.U., Park, H.J., et al. (1996) Hepatitis B and C Virus, Clonorchis Sinensis for the Risk of Liver Cancer: A Case-Control Study in Pusan, Korea. International Journal of Epi-demiology, 25, 933-940.
https://doi.org/10.1093/ije/25.5.933
|
[21]
|
Palmer, W.C. and Patel, T. (2012) Are Common Factors Involved in the Pathogenesis of Primary Liver Cancers? A Meta-Analysis of Risk Factors for Intrahepatic Cholangiocarcinoma. Journal of Hepatology, 57, 69-76.
https://doi.org/10.1016/j.jhep.2012.02.022
|
[22]
|
Tyson, G.L. and El-Serag, H.B. (2011) Risk Factors for Cholangi-ocarcinoma. Hepatology, 54, 173-184.
https://doi.org/10.1002/hep.24351
|
[23]
|
Oh, D.Y., He, A.R., Qin, S., et al. (2022) Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. NEJM Evidence, 1, 1-11. https://doi.org/10.1056/EVIDoa2200015
|
[24]
|
Agarwal, R., Sendilnathan, A., Siddiqi, N.I., et al. (2016) Advanced Biliary Tractcancer: Clinical Outcomes with ABC- 02 Regimen and Analysis of Prognostic Factors in a Tertiary Care Center in the United States. Journal of Gastrointestinal Oncology, 7, 996-1003. https://doi.org/10.21037/jgo.2016.09.10
|
[25]
|
Kim, S.T., Kang, J.H., Lee, J., Lee, H.W., Oh, S.Y., Jang, J.S., Lee, M.A., Sohn, B.S., Yoon, S.Y., Choi, H.J., Hong, J.H., Kim, M.J., Kim, S., Park, Y.S., Park, J.O. and Lim, H.Y. (2019) Capecitabine plus Oxaliplatin versus Gemcitabine plus Oxaliplatin as First-Line Therapy for Advanced Biliary Tract Cancers: A Multicenter, Open-Label, Randomized, Phase III, Noninferiority Trial. Annals of Oncology, 30, 788-795. https://doi.org/10.1093/annonc/mdz058
|
[26]
|
Shroff, R.T., Javle, M.M., Xiao, L., Kaseb, A.O., Varadhachary, G.R., Wolff, R.A., Raghav, K.P.S., Iwasaki, M., Masci, P., Ramanathan, R.K., Ahn, D.H., Bekaii-Saab, T.S. and Borad, M.J. (2019) Gemcitabine, Cisplatin, and Nab-Pac- litaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial. JAMA Oncology, 5, 824-830.
https://doi.org/10.1001/jamaoncol.2019.0270
|
[27]
|
Tan, E.S., Cao, B., Kim, J., Al-Toubah, T.E., Mehta, R., Centeno, B.A. and Kim, R.D. (2021) Phase 2 Study of Copanlisib in Combination with Gemcitabine and Cisplatin in Advanced Biliary Tract Cancers. Cancer, 127, 1293-1300.
https://doi.org/10.1002/cncr.33364
|
[28]
|
Drilon, A., Laetsch, T.W., Kummar, S., DuBois, S.G., Lassen, U.N., De-metri, G.D., Nathenson, M., Doebele, R.C., Farago, A.F., Pappo, A.S., Turpin, B., Dowlati, A., Brose, M.S., Masca-renhas, L., Federman, N., Berlin, J., El-Deiry, W.S., Baik, C., Deeken, J., Boni, V., Nagasubramanian, R., Taylor, M., Rudzinski, E.R., Meric-Bernstam, F., Sohal, D.P.S., Ma, P.C., Raez, L.E., Hechtman, J.F., Benayed, R., Ladanyi, M., Tuch, B.B., Ebata, K., Cruickshank, S., Ku, N.C., Cox, M.C., Hawkins, D.S., Hong, D.S. and Hyman, D.M. (2018) Ef-ficacy of Larotrectinib in TRK Fusion-Posi- tive Cancers in Adults and Children. The New England Journal of Medicine, 378, 731-739.
https://doi.org/10.1056/NEJMoa1714448
|
[29]
|
Marabelle, A., Le, D.T., Ascierto, P.A., Di Giacomo, A.M., De Je-sus-Acosta, A., Delord, J.P., Geva, R., Gottfried, M., Penel, N., Hansen, A.R., Piha-Paul, S.A., Doi, T., Gao, B., Chung, H.C., Lopez-Martin, J., Bang, Y.J., Frommer, R.S., Shah, M., Ghori, R., Joe, A.K., Pruitt, S.K. and Diaz Jr., L.A. (2020) Efficacy of Pembrolizumab in Patients with Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results from the Phase II KEYNOTE-158 Study. Journal of Clinical Oncology, 38, 1-10. https://doi.org/10.1200/JCO.19.02105
|
[30]
|
Doebele, R.C., Drilon, A., Paz-Ares, L., Siena, S., Shaw, A.T., Farago, A.F., Blakely, C.M., Seto, T., Cho, B.C., Tosi, D., Besse, B., Chawla, S.P., Bazhenova, L., Krauss, J.C., Chae, Y.K., Barve, M., Garrido-Laguna, I., Liu, S.V., Conkling, P., John, T., Fakih, M., Sigal, D., Loong, H.H., Buchschacher Jr., G.L., Garrido, P., Nieva, J., Steuer, C., Overbeck, T.R., Bowles, D.W., Fox, E., Riehl, T., Chow-Maneval, E., Simmons, B., Cui, N., Johnson, A., Eng, S., Wilson, T.R. and Demetri, G.D. (2020) Entrectinib in Patients with Advanced or Met-astatic NTRK Fusion-Positive Solid Tumours: Integrated Analysis of Three Phase 1-2 Trials. The Lancet Oncology, 21, 271-282.
https://doi.org/10.1016/S1470-2045(19)30691-6
|
[31]
|
Le, D.T., Durham, J.N., Smith, K.N., Wang, H., Bartlett, B.R., Aulakh, L.K., Lu, S., Kemberling, H., Wilt, C., Luber, B.S., Wong, F., Azad, N.S., Rucki, A.A., Laheru, D., Donehower, R., Zaheer, A., Fisher, G.A., Crocenzi, T.S., Lee, J.J., Greten, T.F., Duffy, A.G., Ciombor, K.K., Eyring, A.D., Lam, B.H., Joe, A., Kang, S.P., Holdhoff, M., Danilova, L., Cope, L., Meyer, C., Zhou, S., Goldberg, R.M., Armstrong, D.K., Bever, K.M., Fader, A.N., Taube, J., Housseau, F., Spetzler, D., Xiao, N., Pardoll, D.M., Papadopou-los, N., Kinzler, K.W., Eshleman, J.R., Vogelstein, B., Anders, R.A. and Diaz Jr., L.A. (2017) Mismatch Repair Defi-ciency Predicts Response of Solid Tumors to PD-1 Blockade. Science, 357, 409-413.
|
[32]
|
Edeline, J., Touchefeu, Y., Guiu, B., et al. (2020) Radioembolization plus Chemotherapy for First-Line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial. JAMA Oncology, 6, 51-59.
https://doi.org/10.1001/jamaoncol.2019.3702
|
[33]
|
Sigurdson, E.R., Ridge, J.A., Kemeny, N. and Daly, J.M. (1987) Tumor and Liver Drug Uptake following Hepatic Artery and Portal Vein Infusion. Journal of Clinical Oncology, 5, 1836-1840.
https://doi.org/10.1200/JCO.1987.5.11.1836
|
[34]
|
Breedis, C. and Young, G. (1954) The Blood Supply of Neo-plasms in the Liver. The American Journal of Pathology, 30, 969-977.
|
[35]
|
Franssen, S., Soares, K.C., Jolissaint, J.S., et al. (2022) Comparison of Hepatic Arterial Infusion Pump Chemotherapy vs Resection for Patients with Multifocal In-trahepatic Cholangiocarcinoma. JAMA Surgery, 157, 590-596.
https://doi.org/10.1001/jamasurg.2022.1298
|
[36]
|
Kim, G.H., Kim, P.H., Kim, J.H., Won, H.J., Shin, Y.M. and Choi, S.H. (2022) Thermal Ablation in the Treatment of Intrahepatic Cholangiocarcinoma: A Systematic Review and Meta-Analysis. European Radiology, 32, 1205-1215.
https://doi.org/10.1007/s00330-021-08216-x
|
[37]
|
Goldaracena, N., Gorgen, A. and Sapisochin, G. (2018) Current Status of Liver Transplantation for Cholangiocarcinoma. Liver Transplantation, 24, 294-303. https://doi.org/10.1002/lt.24955
|
[38]
|
Moris, D., Tsilimigras, D.I., Ntanasis-Stathopoulos, I., et al. (2017) Liver Transplantation in Patients with Liver Metastases from Neuroendocrine Tumors: A Systematic Review. Surgery, 162, 525-536.
https://doi.org/10.1016/j.surg.2017.05.006
|
[39]
|
Moris, D., Tsilimigras, D.I., Chakedis, J., et al. (2017) Liver Transplantation for Unresectable Colorectal Liver Metastases: A Systematic Review. Journal of Surgical Oncology, 116, 288-297. https://doi.org/10.1002/jso.24671
|